Clinical Trials · NCT00049023
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- O'Dorisio, M S
- Enrollment
- 27
- Start date
- Jan 2002
- Locations
- 1 site, United States
- Primary endpoint
- Establish the three-cycle maximum-tolerated dose of 90Y-DOTA-tyr3-Octreotide